4.2 Sedative-Hypnotics and Benzodiazepines

Applying Domain I.D to sedative-hypnotics

Task I.D still has four parts—pharmacology, intoxication and overdose, withdrawal, and physiological, psychological, and social effects—now applied to sedative-hypnotics: benzodiazepines, Z-drugs, and barbiturates. Domain I remains 25% of the ADC Examination (ADC Candidate Guide, effective November 2022, checked 2026-09-20). This section is independent ADC study material by OpenExamPrep. OpenExamPrep does not claim IC&RC approval, partnership, or exact equivalence with IC&RC training.

Northbridge's Dana Ellis admits James Park, age 52. He swallows alprazolam several times a day from a cousin's bottle, takes zolpidem 10 mg plus extras to sleep, and years ago took phenobarbital after a seizure. He says he will just stop everything this weekend because pills are not alcohol. That sentence is how people seize.

Pharmacology: one inhibitory receptor, three teaching families

Benzodiazepines, Z-drugs, and barbiturates all increase GABA-A inhibitory tone, which is why they share cross-tolerance with alcohol (section 3.1) and why combined use multiplies respiratory depression. They are not identical drugs.

• Benzodiazepines are positive allosteric modulators at the benzodiazepine site on GABA-A. They need GABA present to work. Used alone in a healthy adult they have a flatter lethal curve than barbiturates; mixed with alcohol or opioids that margin collapses.
• Z-drugs (zolpidem, zaleplon, eszopiclone) bind a related GABA-A site with more alpha-1 preference. Marketing called them non-benzodiazepine hypnotics. Counselors should still treat them as GABA-A sedative-hypnotics with dependence, rebound insomnia, complex sleep behaviors (sleep-driving, sleep-eating), and withdrawal.
• Barbiturates (phenobarbital, pentobarbital, secobarbital) act at a different GABA-A site and can open the channel more independently of GABA. The therapeutic index is narrower. Overdose is more often fatal. Phenobarbital also induces hepatic enzymes, changing levels of other drugs.

Half-life decides when James looks fine and when the storm arrives.

Trap: clearing James at 24 hours because clonazepam or phenobarbital has not declared itself yet. Another trap: calling zolpidem a vitamin because the bottle says sleep aid.

Intoxication, overdose, and memory blackouts

Intoxication looks like alcohol: sedation, slurred speech, ataxia, nystagmus, impaired attention, and poor judgment. Overdose adds stupor, respiratory depression, hypothermia, and aspiration—especially with alcohol or opioids. Pure benzodiazepine overdose is less often fatal than barbiturate or mixed overdose; do not teach families that any benzo pile is therefore safe. Flumazenil (benzodiazepine-site antagonist) is not routine in mixed or undifferentiated overdose because it can precipitate seizures in dependent people and does not reverse alcohol or opioids (section 3.2).

Memory blackouts on this class are anterograde amnesia: the hippocampus fails to encode new memories while the person may still walk, text, or have sex. Rapid-onset, high-potency agents (alprazolam, triazolam, flunitrazepam where encountered, high-dose zolpidem) are classic. A blackout is not the same as passing out, and it is not proof James is lying when he cannot recall an argument. Combine with alcohol and the amnesia risk climbs. Counselors document, do not shame, and treat the combination as a safety issue.

Physiological effects: falls and hip fractures (especially older adults), motor-vehicle crashes, aspiration, worsening sleep architecture with chronic use, and respiratory depression in lung disease. Psychological effects: emotional flattening, depression, paradoxical disinhibition or rage in some people, rebound anxiety between alprazolam doses, and craving. Social effects: lost work because of grogginess, diverted pills inside families, impaired parenting, and legal trouble from driving or complex sleep behaviors.

Withdrawal: taper versus abrupt stop

Sedative-hypnotic withdrawal rhymes with alcohol: anxiety, tremor, insomnia, perceptual changes, seizures, and delirium. It can kill. Short-acting alprazolam and many Z-drugs announce themselves sooner—often within a day or two. Long-acting diazepam, clonazepam, and phenobarbital can wait until James has already been sent home.

Abrupt stop in a dependent client is not toughness. It is an unsupervised seizure plan. Standard medical teaching is a planned taper, often after substituting a longer-acting benzodiazepine (commonly diazepam) and reducing in small steps over weeks, sometimes months for high-dose or long-duration use. Phenobarbital tapers exist in medical settings; they are not a cousin's leftover bottle. Scope: Dana coordinates medical evaluation. She does not invent a home schedule from James's alprazolam bag, and she does not tell him to skip a day to prove he is not addicted.

Worked Northbridge example: James last took alprazolam Friday morning and zolpidem Friday night. Saturday he is wired and sweating. Sunday he feels briefly better and asks to leave. Monday clonazepam-range timing is still ahead if he also had a long-acting agent in the mix. Kindling from prior alcohol or benzo withdrawals raises risk further.

Sedative-hypnotic traps

1. Treating Z-drugs as non-addictive because they are not named benzodiazepines.
2. Equating barbiturate overdose risk with the flatter curve of a benzodiazepine taken alone.
3. Clearing a clonazepam or phenobarbital client at 24 hours.
4. Coaching abrupt cessation instead of a medically supervised taper.
5. Interpreting blackouts as lying rather than anterograde amnesia.
6. Using flumazenil as if it were naloxone for every pill overdose.